WO2005000202A3 - Compositions and methods for the modulation of the expression of b7 protein - Google Patents

Compositions and methods for the modulation of the expression of b7 protein Download PDF

Info

Publication number
WO2005000202A3
WO2005000202A3 PCT/US2004/015880 US2004015880W WO2005000202A3 WO 2005000202 A3 WO2005000202 A3 WO 2005000202A3 US 2004015880 W US2004015880 W US 2004015880W WO 2005000202 A3 WO2005000202 A3 WO 2005000202A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
expression
modulation
protein
methods
Prior art date
Application number
PCT/US2004/015880
Other languages
French (fr)
Other versions
WO2005000202A2 (en
Inventor
Frank C Bennett
Timothy A Vickers
James G Karras
Susan M Freier
Original Assignee
Isis Pharmaceuticals Inc
Frank C Bennett
Timothy A Vickers
James G Karras
Susan M Freier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/444,206 external-priority patent/US20040023917A1/en
Application filed by Isis Pharmaceuticals Inc, Frank C Bennett, Timothy A Vickers, James G Karras, Susan M Freier filed Critical Isis Pharmaceuticals Inc
Priority to US10/558,216 priority Critical patent/US7960355B2/en
Priority to EP04752823A priority patent/EP1631235A4/en
Publication of WO2005000202A2 publication Critical patent/WO2005000202A2/en
Publication of WO2005000202A3 publication Critical patent/WO2005000202A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Antisense oligonucleotide compositions which specifically hybridize with nucleic acids encoding B7 proteins, and use of these compositions for inhibiting expression of B7 mRNA.
PCT/US2004/015880 2003-05-23 2004-05-19 Compositions and methods for the modulation of the expression of b7 protein WO2005000202A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/558,216 US7960355B2 (en) 2003-05-23 2004-05-19 Compositions and methods for the modulation of the expression of B7 protein
EP04752823A EP1631235A4 (en) 2003-05-23 2004-05-19 Compositions and methods for the modulation of the expression of b7 protein

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/444,206 US20040023917A1 (en) 1996-12-31 2003-05-23 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US10/444,206 2003-05-23
US51061403P 2003-10-10 2003-10-10
US60/510,614 2003-10-10
US52040103P 2003-11-13 2003-11-13
US60/520,401 2003-11-13
US53729104P 2004-01-16 2004-01-16
US60/537,291 2004-01-16

Publications (2)

Publication Number Publication Date
WO2005000202A2 WO2005000202A2 (en) 2005-01-06
WO2005000202A3 true WO2005000202A3 (en) 2006-01-19

Family

ID=33556628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015880 WO2005000202A2 (en) 2003-05-23 2004-05-19 Compositions and methods for the modulation of the expression of b7 protein

Country Status (2)

Country Link
EP (1) EP1631235A4 (en)
WO (1) WO2005000202A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713332A4 (en) * 2004-01-23 2010-08-18 Avi Biopharma Inc Antisense oligomers and methods for inducing immune tolerance and immunosuppression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO2000074687A1 (en) * 1999-06-04 2000-12-14 Isis Pharmaceuticals, Inc. Antisense modulation of b7 protein expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207440D0 (en) * 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319906B1 (en) * 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO2000074687A1 (en) * 1999-06-04 2000-12-14 Isis Pharmaceuticals, Inc. Antisense modulation of b7 protein expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1631235A4 *

Also Published As

Publication number Publication date
WO2005000202A2 (en) 2005-01-06
EP1631235A4 (en) 2008-05-21
EP1631235A2 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
WO2003012057A3 (en) Antisense modulation of serum amyloid a4 expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2006002038A3 (en) Immunostimulatory oligonucleotide multimers
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
EP1248794A4 (en) Antisense modulation of smad7 expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003066805A3 (en) Antisense modulation of complement component c3 expression
WO2003008545A3 (en) Antisense modulation of glioma-associated oncogene-2 expression
WO2006073602A3 (en) Rnai modulation of the bcr-abl fusion gene and uses thereof
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2003057843A3 (en) Methods and materials for modulating trpc4
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2005000202A3 (en) Compositions and methods for the modulation of the expression of b7 protein
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004752823

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004752823

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007135364

Country of ref document: US

Ref document number: 10558216

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10558216

Country of ref document: US